Attenuated viral vector immunogene-based therapy and vaccine (Radient Pharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAttenuated viral vector immunogene-based therapy and vaccine (Radient Pharmaceuticals)
Drug Alias NameGM-CSF/B7-2 gene therapyGM-CSF + CD86 costimulator gene therapy and vaccine
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Live attenuated vaccine
Mechanisms of ActionMacrophage colony stimulating factor 2 modulatorsCluster of differentiation 86 modulators
TargetsCluster of differentiation 86Macrophage colony stimulating factor 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRadient
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRadientJaiva Technologies
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A